{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T15:53:42Z","timestamp":1769097222913,"version":"3.49.0"},"reference-count":25,"publisher":"Tohoku University Medical Press","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Tohoku J. Exp. Med."],"published-print":{"date-parts":[[2018]]},"DOI":"10.1620\/tjem.244.291","type":"journal-article","created":{"date-parts":[[2018,4,9]],"date-time":"2018-04-09T22:08:34Z","timestamp":1523311714000},"page":"291-296","source":"Crossref","is-referenced-by-count":18,"title":["Expression of Placenta Growth Factor Is Associated with Unfavorable Prognosis of Advanced-Stage Serous Ovarian Cancer"],"prefix":"10.1620","volume":"244","author":[{"given":"Qin","family":"Meng","sequence":"first","affiliation":[{"name":"Department of Gynecology and Obstetrics, Shandong Medical College Linyi"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pengjing","family":"Duan","sequence":"additional","affiliation":[{"name":"Department of Gynecology and Obstetrics, Affiliated Hospital of Shandong Medical College Linyi"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lin","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Gynecology and Obstetrics, Linyi People\u2019s Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongmei","family":"Miao","sequence":"additional","affiliation":[{"name":"Department of Gynecology and Obstetrics, Linyi People\u2019s Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"622","reference":[{"key":"1","unstructured":"Barnes, M.N., Grizzle, W.E., Grubbs, C.J. &amp; Partridge, E.E. (2002) Paradigms for primary prevention of ovarian carcinoma. <i>CA Cancer J. Clin.<\/i>, 52, 216-225."},{"key":"2","doi-asserted-by":"crossref","unstructured":"Basu, M., Mukhopadhyay, S., Chatterjee, U. &amp; Roy, S.S. (2014) FGF16 promotes invasive behavior of SKOV-3 ovarian cancer cells through activation of mitogen-activated protein kinase (MAPK) signaling pathway. <i>J. Biol. Chem.<\/i>, 289, 1415-1428.","DOI":"10.1074\/jbc.M113.535427"},{"key":"3","unstructured":"Burger, R.A. (2011) Overview of anti-angiogenic agents in development for ovarian cancer. <i>Gynecol. Oncol.<\/i>, 121, 230-238."},{"key":"4","unstructured":"Cho, K.R. &amp; Shih Ie, M. (2009) Ovarian cancer. <i>Annu. Rev. Pathol.<\/i>, 4, 287-313."},{"key":"5","unstructured":"Colombo, P.E., Fabbro, M., Theillet, C., Bibeau, F., Rouanet, P. &amp; Ray-Coquard, I. (2014) Sensitivity and resistance to treatment in the primary management of epithelial ovarian cancer. <i>Crit. Rev. Oncol. Hematol.<\/i>, 89, 207-216."},{"key":"6","unstructured":"De Falco, S. (2012) The discovery of placenta growth factor and its biological activity. <i>Exp. Mol. Med.<\/i>, 44, 1-9."},{"key":"7","unstructured":"Decio, A., Taraboletti, G., Patton, V., Alzani, R., Perego, P., Fruscio, R., Jurgensmeier, J.M., Giavazzi, R. &amp; Belotti, D. (2014) Vascular endothelial growth factor c promotes ovarian carcinoma progression through paracrine and autocrine mechanisms. <i>Am. J. Pathol.<\/i>, 184, 1050-1061."},{"key":"8","unstructured":"Dewerchin, M. &amp; Carmeliet, P. (2014) Placental growth factor in cancer. <i>Expert Opin. Ther. Targets<\/i>, 18, 1339-1354."},{"key":"9","unstructured":"du Bois, A., Luck, H.J., Meier, W., Adams, H.P., Mobus, V., Costa, S., Bauknecht, T., Richter, B., Warm, M., Schroder, W., Olbricht, S., Nitz, U., Jackisch, C., Emons, G., Wagner, U., et al. (2003) A randomized clinical trial of cisplatin\/paclitaxel versus carboplatin\/paclitaxel as first-line treatment of ovarian cancer. <i>J. Natl. Cancer Inst.<\/i>, 95, 1320-1329."},{"key":"10","doi-asserted-by":"crossref","unstructured":"Fong, P.C., Yap, T.A., Boss, D.S., Carden, C.P., Mergui-Roelvink, M., Gourley, C., De Greve, J., Lubinski, J., Shanley, S., Messiou, C., A\u2019Hern, R., Tutt, A., Ashworth, A., Stone, J., Carmichael, J., et al. (2010) Poly (ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. <i>J. Clin. Oncol.<\/i>, 28, 2512-2519.","DOI":"10.1200\/JCO.2009.26.9589"},{"key":"11","unstructured":"Jeruss, J.S. &amp; Woodruff, T.K. (2009) Preservation of fertility in patients with cancer. <i>N. Engl. J. Med.<\/i>, 360, 902-911."},{"key":"12","doi-asserted-by":"crossref","unstructured":"Kendall, R.L. &amp; Thomas, K.A. (1993) Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. <i>Proc. Natl. Acad. Sci. USA<\/i>, 90, 10705-10709.","DOI":"10.1073\/pnas.90.22.10705"},{"key":"13","doi-asserted-by":"crossref","unstructured":"Khalil, A., Muttukrishna, S., Harrington, K. &amp; Jauniaux, E. (2008) Effect of antihypertensive therapy with alpha methyldopa on levels of angiogenic factors in pregnancies with hypertensive disorders. <i>PLoS One<\/i>, 3, e2766.","DOI":"10.1371\/journal.pone.0002766"},{"key":"14","unstructured":"Landen, C.N. Jr., Chavez-Reyes, A., Bucana, C., Schmandt, R., Deavers, M.T., Lopez-Berestein, G. &amp; Sood, A.K. (2005) Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery. <i>Cancer Res.<\/i>, 65, 6910-6918."},{"key":"15","doi-asserted-by":"crossref","unstructured":"Liu, H., Xu, Y., Zhang, Q., Li, K., Wang, D., Li, S., Ning, S., Yang, H., Shi, W., Liu, Z. &amp; Chen, Y. (2017a) Correlations between TBL1XR1 and recurrence of colorectal cancer. <i>Sci. Rep.<\/i>, 7, 44275.","DOI":"10.1038\/srep44275"},{"key":"16","doi-asserted-by":"crossref","unstructured":"Liu, H., Xu, Y., Zhang, Q., Yang, H., Shi, W., Liu, Z., Li, K., Gong, Z., Ning, S., Li, S. &amp; Chen, Y. (2017b) Prognostic significance of TBL1XR1 in predicting liver metastasis for early stage colorectal cancer. <i>Surg. Oncol.<\/i>, 26, 13-20.","DOI":"10.1016\/j.suronc.2016.12.003"},{"key":"17","doi-asserted-by":"crossref","unstructured":"Rolny, C., Mazzone, M., Tugues, S., Laoui, D., Johansson, I., Coulon, C., Squadrito, M.L., Segura, I., Li, X., Knevels, E., Costa, S., Vinckier, S., Dresselaer, T., Akerud, P., De Mol, M., et al. (2011) HRG inhibits tumor growth and metastasis by inducing macrophage polarization and vessel normalization through downregulation of PlGF. <i>Cancer Cell<\/i>, 19, 31-44.","DOI":"10.1016\/j.ccr.2010.11.009"},{"key":"18","unstructured":"Song, N., Liu, H., Ma, X. &amp; Zhang, S. (2015) Placental growth factor promotes metastases of ovarian cancer through MiR-543-regulated MMP7. <i>Cell. Physiol. Biochem.<\/i>, 37, 1104-1112."},{"key":"19","unstructured":"Song, N., Liu, H., Ma, X. &amp; Zhang, S. (2016) Placental growth factor promotes ovarian cancer cell invasion via ZEB2. <i>Cell. Physiol. Biochem.<\/i>, 38, 351-358."},{"key":"20","doi-asserted-by":"crossref","unstructured":"Wang, K., Stark, F.S., Schlothauer, T., Lahr, A., Cosson, V., Zhi, J., Habben, K., Tessier, J., Schick, E., Staack, R.F. &amp; Krieter, O. (2017) An apparent clinical pharmacokinetic drug-drug interaction between bevacizumab and the anti-placental growth factor monoclonal antibody RO5323441 via a target-trapping mechanism. <i>Cancer Chemother. Pharmacol.<\/i>, 79, 661-671.","DOI":"10.1007\/s00280-017-3242-8"},{"key":"21","doi-asserted-by":"crossref","unstructured":"Xu, Y., Yang, X., Li, Z., Li, S., Guo, S., Ismail, S., Liu, H., Huang, Z., Zhang, Z., Chen, Y. &amp; Sun, Q. (2017) Sprouty2 correlates with favorable prognosis of gastric adenocarcinoma via suppressing FGFR2-induced ERK phosphorylation and cancer progression. <i>Oncotarget<\/i>, 8, 4888-4900.","DOI":"10.18632\/oncotarget.13982"},{"key":"22","unstructured":"Xu, Y.F., Yang, X.Q., Lu, X.F., Guo, S., Liu, Y., Iqbal, M., Ning, S.L., Yang, H., Suo, N. &amp; Chen, Y.X. (2014) Fibroblast growth factor receptor 4 promotes progression and correlates to poor prognosis in cholangiocarcinoma. <i>Biochem. Biophys. Res. Commun.<\/i>, 446, 54-60."},{"key":"23","unstructured":"Yang, X.Q., Xu, Y.F., Guo, S., Liu, Y., Ning, S.L., Lu, X.F., Yang, H. &amp; Chen, Y.X. (2014) Clinical significance of nerve growth factor and tropomyosin-receptor-kinase signaling pathway in intrahepatic cholangiocarcinoma. <i>World J. Gastroenterol.<\/i>, 20, 4076-4084."},{"key":"24","unstructured":"Yap, T.A., Carden, C.P. &amp; Kaye, S.B. (2009) Beyond chemotherapy: targeted therapies in ovarian cancer. <i>Nat. Rev. Cancer<\/i>, 9, 167-181."},{"key":"25","unstructured":"Zaid, T.M., Yeung, T.L., Thompson, M.S., Leung, C.S., Harding, T., Co, N.N., Schmandt, R.S., Kwan, S.Y., Rodriguez-Aguay, C., Lopez-Berestein, G., Sood, A.K., Wong, K.K., Birrer, M.J. &amp; Mok, S.C. (2013) Identification of FGFR4 as a potential therapeutic target for advanced-stage, high-grade serous ovarian cancer. <i>Clin. Cancer Res.<\/i>, 19, 809-820."}],"container-title":["The Tohoku Journal of Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/tjem\/244\/4\/244_291\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,31]],"date-time":"2020-10-31T11:11:05Z","timestamp":1604142665000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/tjem\/244\/4\/244_291\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018]]},"references-count":25,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1620\/tjem.244.291","relation":{},"ISSN":["0040-8727","1349-3329"],"issn-type":[{"value":"0040-8727","type":"print"},{"value":"1349-3329","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018]]}}}